- Home
- LCTX vs GRX Comparison
LCTX vs GRX Comparison
Compare LCTX & GRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- GRX
- Stock Information
- Founded
- LCTX 1990
- GRX 2007
- Country
- LCTX United States
- GRX United States
- Employees
- LCTX N/A
- GRX N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- GRX Finance/Investors Services
- Sector
- LCTX Health Care
- GRX Finance
- Exchange
- LCTX Nasdaq
- GRX Nasdaq
- Market Cap
- LCTX 165.6M
- GRX 160.8M
- IPO Year
- LCTX N/A
- GRX N/A
- Fundamental
- Price
- LCTX $0.91
- GRX $11.03
- Analyst Decision
- LCTX Strong Buy
- GRX
- Analyst Count
- LCTX 3
- GRX 0
- Target Price
- LCTX $5.67
- GRX N/A
- AVG Volume (30 Days)
- LCTX 409.3K
- GRX 39.7K
- Earning Date
- LCTX 08-08-2024
- GRX 01-01-0001
- Dividend Yield
- LCTX N/A
- GRX 5.98%
- EPS Growth
- LCTX N/A
- GRX N/A
- EPS
- LCTX N/A
- GRX 0.26
- Revenue
- LCTX $6,186,000.00
- GRX N/A
- Revenue This Year
- LCTX N/A
- GRX N/A
- Revenue Next Year
- LCTX $119.00
- GRX N/A
- P/E Ratio
- LCTX N/A
- GRX $38.50
- Revenue Growth
- LCTX N/A
- GRX N/A
- 52 Week Low
- LCTX $0.77
- GRX $7.73
- 52 Week High
- LCTX $1.61
- GRX $10.40
- Technical
- Relative Strength Index (RSI)
- LCTX 52.00
- GRX 65.22
- Support Level
- LCTX $0.83
- GRX $10.68
- Resistance Level
- LCTX $0.94
- GRX $11.15
- Average True Range (ATR)
- LCTX 0.06
- GRX 0.13
- MACD
- LCTX 0.01
- GRX -0.02
- Stochastic Oscillator
- LCTX 64.77
- GRX 67.65
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About GRX The Gabelli Healthcare & Wellness Trust of Beneficial Interest
Gabelli Healthcare & WellnessRx Trust operates as a diversified closed-end management investment company. The investment objective of the fund is the long-term growth of capital. The fund invests at least its assets in equity securities and income-producing securities of domestic and foreign companies in the healthcare and wellness industries. It invests in various sectors, of which Health Care Providers & Services, Food, Health Care Equipment and Supplies, and Pharmaceuticals account for the majority of the weightage.